Graymark Healthcare Reports Full Year 2011 Financial Results
(firmenpresse) - OKLAHOMA CITY, OK -- (Marketwire) -- 03/29/12 -- Graymark Healthcare, Inc. (NASDAQ: GRMH), the nation's second largest provider of diagnostic sleep services and an innovator in comprehensive care for obstructive sleep apnea (OSA), reported financial results for the full year ended December 31, 2011.
in 2011 were $17.5 million, decreasing 15% from $20.5 million in 2010 (as adjusted for the discontinued operations including the company's retail pharmacy business and the sale of Nocturna East Sleep Centers).
were $12.6 million, decreasing 16% from $15.0 million in 2010.
The decrease was primarily the result of decreased reimbursement driven by a shift from out-of-network to in-network reimbursements beginning in the third quarter of 2010, an increase in the percentage of sleep studies performed at hospital-based locations, and the closing of unprofitable free-standing facilities partially offset by increased revenues from the company's newly added hospital-based management locations.
were $5.0 million, decreasing 11% from $5.6 million in 2010. The decrease was due to lower conversion rates of sleep studies to CPAP set-ups along with a decline in reimbursement levels, partially offset by an increase in the company's re-supply revenue. In addition to the company's customary quarterly shipments, during the third quarter the company initiated monthly shipments, where permitted by payers, resulting in lower average revenues per shipment as monthly shipments are significantly smaller in dollar amount.
decreased $2.1 million or 13% to $13.7 million, compared to $15.8 million in 2010. This decrease was primarily due to staff reductions related to the centralization of billing and scheduling functions, reductions of executive staff, right-sizing of operating facilities, including renegotiations of facility leases and the consolidation of unprofitable locations.
decreased 50% to $0.9 million from $1.8 million in 2010. This decrease is the result of the centralization of billing and collections functions and the increased focus on collections of old balances.
Loss from continuing operations, net of taxes, was $6.4 million in 2011, compared to a loss from continuing operations of $15.7 million in 2010 including $8.8 million of impairment write downs. Net loss attributable to Graymark was $5.9 million or $(0.51) per share in 2011, compared to a net loss of $19.1 million or $(2.64) per share in 2010.
Adjusted EBITDA from continuing operations in 2011 was a loss of $3.7 million, compared to a loss of $3.8 million in 2010 (see "Reconciliation of Non-GAAP Financial Measures" below for the definition and an important discussion of this non-GAAP financial measure).
At December 31, 2011, cash and cash equivalents totaled $4.9 million, compared to $639,000 at December 31, 2010. It should also be noted the cash balances do not reflect monies held in an escrow account related to the sale of our retail pharmacy business in the amounts of $1.0 million and $2.0 million in 2011 and 2010 respectively. The company received $1.0 million of these monies in December 2011 and is scheduled to receive $1.0 million in June 2012.
At December 31, 2011 current assets totaled $9.8 million as compared to $7.6 million at December 31, 2010 and current liabilities totaled $22.8 million compared to $28.1 million in 2010. Working capital was a $13.0 million deficit at December 31, 2011 compared to a $20.5 million deficit at December 31, 2010.
This release reflects the classification of the Arvest credit facility as a current liability consistent with our presentation as of December 31, 2010. The company is currently negotiating an amendment to the Amended and Restated Loan Agreement with Arvest. The proposed amendment would, among other things, have the effect of granting a waiver of the debt service coverage ratio until March 31, 2013. The currently proposed amendment would allow Graymark to classify approximately $17.0 million of the Arvest credit facility as long term debt. While Graymark believes that the proposed amendment will be finalized and approved by Arvest in the next week, there can be no assurances that Graymark and Arvest will be able to enter into an acceptable amendment in that timeframe or at all.
As of December 31, 2011, our total debt was $19.3 million, compared to $23.2 million at December 31, 2010.
"2011 was an important year of right-sizing the expense structure of Graymark Healthcare as we saved $3.0 million in SG&A and bad debt expense since the beginning of 2011," said Stanton Nelson, CEO of Graymark Healthcare. "A major project included within this initiative was the centralization of our verification of benefits and scheduling process. This initiative has already helped improve our volume of sleeps studies performed as we realized a 7% increase in the second half of 2011.
"As we advance through 2012, our focus continues to be increasing the number of sleep studies performed at each of our locations and increasing our conversion percentage related to CPAP equipment sales and ultimately to re-supply revenue. In fact, we estimate our sleep study volume will be up approximately 20% in the first quarter of 2012 compared to the first quarter of 2011. We also expect to further penetrate both the Atlanta and Dallas-Fort Worth markets. We anticipate opening four to six additional locations in the Atlanta and Dallas Fort Worth markets to better serve our referring physicians and their patients. Our team has great confidence that the sleep management market is ripe for consolidation and Graymark is best situated to gain significant market share."
Graymark is providing EBITDA from continuing operations information, which is defined as net income from continuing operations plus interest, income taxes, depreciation and amortization expenses, and adjusted EBITDA from continuing operations which is defined as EBITDA from continuing operations plus impairment of goodwill and intangible assets, property and equipment and equity investment, as well as stock-based compensation expense, as a complement to GAAP results. EBITDA and adjusted EBITDA are commonly used by management and investors as a measure of leverage capacity, debt service ability and liquidity. EBITDA and adjusted EBITDA are not considered measures of financial performance under U.S. generally accepted accounting principles (GAAP), and the items excluded from EBITDA and adjusted EBITDA are significant components in understanding and assessing the company's financial performance. EBITDA and adjusted EBITDA should not be considered in isolation or as an alternative to, or superior to, such GAAP measures as net income, cash flows provided by or used in operating, investing or financing activities, or other financial statement data presented in the company's consolidated financial statements as an indicator of financial performance or liquidity. Reconciliations of non-GAAP financial measures are provided in this news release in the accompanying tables. Since EBITDA and adjusted EBITDA are not measures determined in accordance with GAAP and is susceptible to varying calculations, EBITDA and adjusted EBITDA, as presented, may not be comparable to other similarly titled measures of other companies.
The company will host a conference call to discuss its full year 2011 financial results today (March 29, 2012) at 4:30 p.m.Eastern time.
Dial-In Number: 1-888-846-5003
International: 1-480-629-9856
Conference ID#: 4526724
The conference call will be broadcast live at and available for replay via the investors section of the company's website at
Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Liolios Group at 1-949-574-3860.
A replay of the call will be available on the same day after 7:30 p.m. Eastern time on the same day and until April 29, 2012.
Toll-free replay number: 1-877-870-5176
International replay number: 1-858-384-5517
Replay pin number: 4526724
Headquartered in Oklahoma City, Okla., Graymark Healthcare, Inc. (NASDAQ: GRMH) is the nation's second largest provider of sleep management solutions. In addition to diagnosing and treating over 80 sleep disorders, the company specializes in comprehensive care for Obstructive Sleep Apnea (OSA). Graymark offers its services through 101 sleep laboratories primarily in the Midwest, including standalone or IDTF facilities, therapy facilities, rural outreach hospital sites and urban hospital management agreements. For more information, visit .
This press release contains forward-looking statements that are based on the company's current expectations, forecasts and assumptions. Forward-looking statements involve risks and uncertainties that could cause actual outcomes and results to differ materially from the company's expectations, forecasts and assumptions. These risks and uncertainties include risks and uncertainties not in the control of the company, including, without limitation, the current economic climate, the ability of the company to consummate an acceptable amendment to its Arvest credit facility and other risks and uncertainties, including those enumerated and described in the company's filings with the Securities and Exchange Commission, which filings are available on the SEC's website at . Unless otherwise required by law, the company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Graymark Healthcare, Inc.
Stanton Nelson
Chairman and CEO
Tel 1-405-601-5300
Liolios Group, Inc.
Scott Liolios or Cody Slach
Tel 1-949-574-3860
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 29.03.2012 - 14:05 Uhr
Sprache: Deutsch
News-ID 1098107
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
OKLAHOMA CITY, OK
Phone:
Kategorie:
Hospitals, Facilities and Providers
Anmerkungen:
Diese Pressemitteilung wurde bisher 130 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Graymark Healthcare Reports Full Year 2011 Financial Results
"
steht unter der journalistisch-redaktionellen Verantwortung von
Graymark Healthcare, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
